Medications for Methamphetamine Use Disorder: What Works Now

Methamphetamine use disorder is hard to treat, and you may already know that if you or someone you care about has tried to quit before. Cravings can hit fast. Sleep, mood, and judgment can get knocked off course. That is why medications for methamphetamine use disorder matter now. They are not a magic fix, and they are not the whole plan. But they can help lower use, reduce craving, and give treatment a better shot at sticking.

The old story was simple. There was no medication that helped. That is no longer the full picture. Research has moved, cautiously but clearly, toward combination approaches and better symptom control. What should you make of that if you are trying to choose care? Start with the evidence, then match treatment to the person in front of you.

What to know about medications for methamphetamine use disorder

No single drug is approved as a cure. Treatment usually combines medicine with counseling or contingency management.
Some combinations show promise. Studies have found benefits from naltrexone plus bupropion for some adults.
Supportive medications can matter. Sleep, anxiety, depression, and agitation often need direct treatment.
Care has to be individualized. Meth use often overlaps with stimulant crashes, trauma, ADHD, and other substance use.

Why medications for methamphetamine use disorder are getting more attention

For years, clinicians had to tell patients there was no approved medication with solid evidence for methamphetamine use disorder. That message was honest, but incomplete. Trials have now shown that certain drugs, especially in combination, can help some people cut down use or stay in treatment longer.

The strongest signal so far has come from a combination of extended-release naltrexone and bupropion. A 2021 study published in New England Journal of Medicine found that the combo helped more participants achieve a meaningful response than placebo, although the overall response rate was still modest. That detail matters. This is progress, not a cure. But progress counts.

The real shift is not hype. It is that meth treatment is finally moving from “nothing works” to “some things help, if you use them well.”

Which medications are being used, and why?

Look, the medication list is not long. That is part of the problem. But the options that do exist can still make care better when they are used for the right reasons.

Naltrexone plus bupropion

This is the combination getting the most attention. Naltrexone is better known for alcohol and opioid use disorder. Bupropion is an antidepressant and smoking cessation aid. Together, they may help reduce meth use and blunt the reward signal that keeps the cycle going.

It is not a fit for everyone. Naltrexone cannot be used if someone is currently using opioids or is physically dependent on them. Bupropion also needs careful screening, especially if there is a seizure history or a pattern of heavy alcohol withdrawal.

Other medications under study

Researchers have looked at mirtazapine, modafinil, topiramate, and other agents. Some studies show small benefits, but results are mixed. Why so inconsistent? Meth use disorder is not one neat condition. Patterns of use, housing stability, mental health, and co-use of alcohol or fentanyl all change the picture.

That makes this field feel a bit like building a bridge in shifting sand. You can lay strong beams, but the ground still moves.

What medications can help besides craving reduction?

Some people expect a medication to block meth directly. That is too narrow. Treatment often needs to target the fallout too. Sleep loss, anxiety, irritability, depression, and psychosis can all make relapse more likely. Treating those symptoms can improve the odds that someone stays engaged long enough to benefit from recovery support.

For example, a patient who cannot sleep for days after stopping meth may seem “noncompliant” when the real problem is an untreated crash. Another person may keep using because they are trying to self-manage depression or untreated ADHD. If you miss the driver, you miss the treatment.

How care works best in real life

Start with a full assessment. Ask about meth pattern, other substances, mood symptoms, psychosis, sleep, pain, and medications already in use.
Match medicine to the risk profile. Check for opioid use, seizure risk, blood pressure issues, and mental health history before picking a drug.
Add behavioral treatment. Contingency management has some of the strongest evidence for stimulant use disorders. Counseling helps too, especially when it is specific and consistent.
Track response early. Look for changes in use, craving, sleep, attendance, and stability. Do not wait months to see if a plan is failing.

Timing matters. If a medication is working, you should usually see some signal. Maybe not dramatic. But some signal.

What should you ask a clinician?

Bring direct questions. The best care teams expect them.

Which medication options fit my health history?
What side effects should I watch for?
How will we know if this is helping?
What other supports will I get besides medication?
What happens if cravings or use return?

And ask one more question if the answer feels vague: what is the plan if this first choice fails? Good treatment should have a second step.

What this means for families and support people

If you are helping someone else, avoid framing medication as a shortcut. It is more like a cast on a broken arm. It supports healing, but the person still needs follow-up, structure, and time. Try to focus on practical help. Ride to appointments. Help track doses. Reduce chaos at home if you can.

Also, be realistic about relapse. A return to use does not mean treatment failed. It usually means the plan needs adjustment. Families often need that reminder as much as patients do.

Where the field is headed next

The big question is not whether one pill will fix methamphetamine use disorder. It will not. The better question is which medication combinations, paired with behavioral care, help the largest number of people stay alive, stable, and engaged. That is the bar.

Right now, the evidence points to cautious optimism. Not victory. Not hype. If you are a patient, family member, or clinician, the next step is simple. Ask what is available locally, ask what the data show, and ask how the plan will adapt if the first attempt falls short.

That is where the real work begins.